Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 212

1.

Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review.

Kennedy GA, Tey SK, Cobcroft R, Marlton P, Cull G, Grimmett K, Thomson D, Gill D.

Br J Haematol. 2002 Nov;119(2):412-6.

PMID:
12406079
2.

Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy.

Maeshima AM, Taniguchi H, Nomoto J, Maruyama D, Kim SW, Watanabe T, Kobayashi Y, Tobinai K, Matsuno Y.

Cancer Sci. 2009 Jan;100(1):54-61. doi: 10.1111/j.1349-7006.2008.01005.x. Epub 2008 Nov 25.

3.

The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy.

Rawal YB, Nuovo GJ, Frambach GE, Porcu P, Baiocchi RA, Magro CM.

J Cutan Pathol. 2005 Oct;32(9):616-21.

PMID:
16176299
4.

Loss of CD20 expression in relapsed lymphomas after rituximab therapy.

Haidar JH, Shamseddine A, Salem Z, Mrad YA, Nasr MR, Zaatari G, Bazarbachi A.

Eur J Haematol. 2003 May;70(5):330-2.

PMID:
12694172
5.
6.
7.

[Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].

Huang HQ, Bu Q, Xia ZJ, Lin XB, Wang FH, Li YH, Peng YL, Pan ZH, Wang SS, Lin TY, Jiang WQ, Guan ZZ.

Ai Zheng. 2006 Apr;25(4):486-9. Chinese.

PMID:
16613686
8.

Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantation.

Pan D, Moskowitz CH, Zelenetz AD, Straus D, Kewalaramani T, Noy A, Qin J, Teruya-Feldstein J, Portlock CS.

Cancer J. 2002 Sep-Oct;8(5):371-6.

PMID:
12416894
9.

CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.

Alvaro-Naranjo T, Jaén-Martínez J, Gumá-Padró J, Bosch-Príncep R, Salvadó-Usach MT.

Ann Hematol. 2003 Sep;82(9):585-8. Epub 2003 Jul 31.

PMID:
12898184
10.

[Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma].

Zhang HY, Lin TY, Jiang WQ, Zhang L, Huang HQ, Xia ZJ, Sun XF, He YJ, Guan ZZ.

Ai Zheng. 2004 Dec;23(12):1681-6. Chinese.

PMID:
15601560
12.

Systemic therapy with cyclophosphamide and anti-CD20 antibody (rituximab) in relapsed primary cutaneous B-cell lymphoma: a report of 7 cases.

Fierro MT, Savoia P, Quaglino P, Novelli M, Barberis M, Bernengo MG.

J Am Acad Dermatol. 2003 Aug;49(2):281-7.

PMID:
12894078
13.

[Rituximab resistance in B-cell lymphoma and its elimination].

Hatake K, Terui Y.

Gan To Kagaku Ryoho. 2009 Apr;36(4):548-51. Japanese.

PMID:
19381025
14.

The therapeutic use of rituximab in non-Hodgkin's lymphoma.

Marcus R, Hagenbeek A.

Eur J Haematol Suppl. 2007 Jan;(67):5-14. Review.

PMID:
17206982
15.
16.

Lymphocyte subsets and viral load in patients with HIV-associated non-Hodgkin's lymphoma treated with anti-CD20 monoclonal antibody and chemotherapy.

De Paoli P, Vaccher E, Tedeschi R, Caffau C, Zanussi S, Bortolin MT, Crepaldi C, Spina M, Tirelli U.

Cancer Immunol Immunother. 2001 May;50(3):157-62.

PMID:
11419183
17.

Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin's lymphoma: initial experience.

Bienert M, Reisinger I, Srock S, Humplik BI, Reim C, Kroessin T, Avril N, Pezzutto A, Munz DL.

Eur J Nucl Med Mol Imaging. 2005 Oct;32(10):1225-33. Epub 2005 Jun 4.

PMID:
15937686
18.

Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy.

Clarke LE, Bayerl MG, Ehmann WC, Helm KF.

J Cutan Pathol. 2003 Aug;30(7):459-62.

PMID:
12859745
19.

Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.

Gellrich S, Muche JM, Wilks A, Jasch KC, Voit C, Fischer T, Audring H, Sterry W.

Br J Dermatol. 2005 Jul;153(1):167-73. Review.

PMID:
16029344
20.

The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy.

Zhou X, Hu W, Qin X.

Oncologist. 2008 Sep;13(9):954-66. doi: 10.1634/theoncologist.2008-0089. Epub 2008 Sep 8. Review.

Supplemental Content

Support Center